Literature DB >> 22744762

Mesenchymal stem cells neither fully acquire the electrophysiological properties of mature cardiomyocytes nor promote ventricular arrhythmias in infarcted rats.

Feng Wei1, Ting-Zhong Wang, Jing Zhang, Zu-Yi Yuan, Hong-Yan Tian, Ya-Juan Ni, Xiao-Zhen Zhuo, Ke Han, Yu Liu, Qun Lu, Hong-Yuan Bai, Ai-Qun Ma.   

Abstract

Electrophysiological properties of implanted mesenchymal stem cells (MSCs) in infarcted hearts remain unclear, and their proarrhythmic effect is still controversial. The intent of this study was to investigate electrophysiological properties and proarrhythmic effects of MSCs in infarcted hearts. Rats were randomly divided into a myocardial infarction (MI) group, a MI-DMEM group (received DMEM medium injection) and MI-MSCs group (received MSCs injection). Survival analysis showed that the majority of engrafted MSCs died at day 9 after transplantation. Engrafted MSCs expressed cardiac markers (MYH, cTnI, Cx43), cardiac ion channel genes (Kv1.4, Kv4.2 and Kir2.1) and potassium currents (I (to), I (K1) and I (KDR)), but did not express Nav1.5, Cav1.2, Na(+) current and Ca(2+) current during their survival. When induced by Ca(2+), implanted MSCs exhibited no contraction ability after being isolated from the heart. Following 8-week electrocardiography monitoring, the cumulative occurrence of ventricular arrhythmias (VAs) was not different among the three groups. However, the prolonged QRS duration in infarcted rats without VAs was significantly decreased in the MI-MSCs group compared with the other two groups. The inducibility of VAs in the MI-MSCs group was much lower than that in the MI and MI-DMEM groups (41.20 vs. 86.67 % and 92.86 %; P < 0.0125). The ventricular effective refractory period in MI-MSCs group was prolonged in comparison with that in the MI and MI-DMEM groups (56.0 ± 8.8 vs. 47.7 ± 8.8 ms and 45.7 ± 6.2 ms; P < 0.01). These results demonstrate that MSCs do not acquire the electrophysiological properties of mature cardiomyocytes during the survival period in the infarcted hearts. However, they can alleviate the electrical vulnerability and do not promote ventricular arrhythmias.

Entities:  

Mesh:

Year:  2012        PMID: 22744762     DOI: 10.1007/s00395-012-0274-4

Source DB:  PubMed          Journal:  Basic Res Cardiol        ISSN: 0300-8428            Impact factor:   17.165


  8 in total

1.  Functions of Mesenchymal Stem Cells in Cardiac Repair.

Authors:  Selçuk Öztürk; Ayşe Eser Elçin; Yaşar Murat Elçin
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

2.  Mesenchymal Stem Cells in Cardiology.

Authors:  Ian A White; Cristina Sanina; Wayne Balkan; Joshua M Hare
Journal:  Methods Mol Biol       Date:  2016

3.  Immunological effect induced by mesenchymal stem cells in a rat liver transplantation model.

Authors:  Zhenqiang Sun; Tao Li; Hao Wen; Haijiang Wang; Weizheng Ji; Yan Ma
Journal:  Exp Ther Med       Date:  2015-06-05       Impact factor: 2.447

Review 4.  The potential of cell-based therapy for diabetes and diabetes-related vascular complications.

Authors:  Aaron Liew; Timothy O'Brien
Journal:  Curr Diab Rep       Date:  2014-03       Impact factor: 4.810

5.  Intramyocardial cell delivery: observations in murine hearts.

Authors:  Tommaso Poggioli; Padmini Sarathchandra; Nadia Rosenthal; Maria P Santini
Journal:  J Vis Exp       Date:  2014-01-24       Impact factor: 1.355

Review 6.  Restoring heart function and electrical integrity: closing the circuit.

Authors:  Luís Miguel Monteiro; Francisco Vasques-Nóvoa; Lino Ferreira; Perpétua Pinto-do-Ó; Diana Santos Nascimento
Journal:  NPJ Regen Med       Date:  2017-04-07

Review 7.  Learning from Mother Nature: Innovative Tools to Boost Endogenous Repair of Critical or Difficult-to-Heal Large Tissue Defects.

Authors:  Ranieri Cancedda; Sveva Bollini; Fiorella Descalzi; Maddalena Mastrogiacomo; Roberta Tasso
Journal:  Front Bioeng Biotechnol       Date:  2017-04-28

8.  Potential of mesenchymal- and cardiac progenitor cells for therapeutic targeting of B-cells and antibody responses in end-stage heart failure.

Authors:  Patricia van den Hoogen; Saskia C A de Jager; Emma A Mol; Arjan S Schoneveld; Manon M H Huibers; Aryan Vink; Pieter A Doevendans; Jon D Laman; Joost P G Sluijter
Journal:  PLoS One       Date:  2019-12-31       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.